Department of Anesthesiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Department of Anesthesiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
J Cardiothorac Vasc Anesth. 2022 Sep;36(9):3587-3595. doi: 10.1053/j.jvca.2022.04.051. Epub 2022 May 9.
To compare the efficacy, safety, and side effects of hydromorphone and morphine administered as patient-controlled analgesia (PCA) for postoperative pain therapy after cardiac surgery with median sternotomy.
A retrospective analysis of data from 2 prospective, single-blinded, randomized trials.
A single-center intensive care unit at a university hospital.
Forty-one adult patients undergoing cardiac surgery with median sternotomy.
Postoperative pain therapy at the intensive care unit was performed by PCA with intravenously administered bolus doses of 0.2 mg of hydromorphone (n = 21) or 2 mg of morphine (n = 20).
Pain at rest and under deep inspiration regularly was assessed using the 11-point numerical rating scale (NRS). Blood pressure, heart rate, cardiac output, oxygen saturation, and respiratory rate were monitored, and adverse events were registered. The median (range) NRS rating at rest was 1.5 (0-5) after hydromorphone and 0.5 (0-5) after morphine, respectively (p = 0.41). The median NRS rating under deep inspiration was 3 (0-6) after hydromorphone and 4 (0-7) after morphine, respectively (p = 0.074). The dose ratio of morphine to hydromorphone during PCA was 5.7 (95% confidence interval: 2.9-7.6). Hemodynamics and respiration were stable and did not differ significantly. Postoperative nausea and vomiting were the most frequent adverse events, which were observed in 29% of the patients after hydromorphone and in 35% after morphine, respectively (p = 0.74).
There were no significant differences in analgesic efficacy and safety between hydromorphone and morphine when used for postoperative pain therapy with PCA after cardiac surgery with median sternotomy.
比较经静脉患者自控镇痛(PCA)给予氢吗啡酮和吗啡用于正中劈开胸骨心脏手术后的术后疼痛治疗的疗效、安全性和副作用。
对 2 项前瞻性、单盲、随机试验数据的回顾性分析。
大学医院的单一中心重症监护病房。
41 名接受正中劈开胸骨心脏手术的成年患者。
在重症监护病房,通过 PCA 给予静脉推注 0.2 毫克氢吗啡酮(n = 21)或 2 毫克吗啡(n = 20)进行术后疼痛治疗。
使用 11 点数字评分量表(NRS)定期评估静息和深呼吸时的疼痛。监测血压、心率、心输出量、血氧饱和度和呼吸频率,并记录不良事件。氢吗啡酮治疗后的静息时 NRS 评分中位数(范围)为 1.5(0-5),而吗啡治疗后的 NRS 评分为 0.5(0-5)(p = 0.41)。氢吗啡酮治疗后的深呼吸时 NRS 评分中位数为 3(0-6),吗啡治疗后的 NRS 评分为 4(0-7)(p = 0.074)。PCA 时吗啡与氢吗啡酮的剂量比为 5.7(95%置信区间:2.9-7.6)。血流动力学和呼吸稳定,无显著差异。术后恶心和呕吐是最常见的不良事件,分别在 29%的氢吗啡酮治疗患者和 35%的吗啡治疗患者中观察到(p = 0.74)。
在正中劈开胸骨心脏手术后,经静脉 PCA 给予氢吗啡酮和吗啡用于术后疼痛治疗时,在镇痛效果和安全性方面无显著差异。